LESCOL 94% SALES GROWTH WORLDWIDE SHOWS VITALITY OF LIPID-LOWERING MARKET; MERCK's ZOCOR UP 79% IN U.S. TO $375 MIL., BUT 1ST QUARTER LAGS 4TH QUARTER
Executive Summary
Strong first quarter sales figures for Novartis' Lescol (fluvastatin) exemplify the vitality of the cholesterol-lowering market during the launch period for the new Warner-Lambert/Pfizer entry Lipitor and in anticipation of the potential mid-year entry of Bayer's cerivastatin.